licanumab
treatment
5 mentions
4 recordings
first heard May 2023
last heard 13 Jul
↑2 vs the 12 months before
Monoclonal antibody approved for Alzheimer’s, marketed as Lecanemab
Trend
Peak in the week of 11 Jul — 2 mentions across 1 series.
Moments
newest first · ▶ plays the momentGayatri Devi, M.D.The Peter Attia Drive · #399 ‒ The evolution of Alzheimer's disease and dementia c... · 56:44 · 13 Jul
…Licanumab is a once-every-two-week drug intravenously.…
Peter Attia, M.D.The Peter Attia Drive · #399 ‒ The evolution of Alzheimer's disease and dementia c... · 2:43 · 13 Jul
…We talk about anti-amyloid therapies, which have become very controversial, although slightly less so today than when they were initially released, including licanumab and decanumab, their risks and benefits, and her approach to reducing side effects, including the most devastating side effects, which we talk about.…
Eric WideraGeriPal - A Geriatrics and Palliative Medicine Podcast · Alzheimer's Definitions, Biomarkers, and Antibodies: Halima ... · 23:25 · 12 Mar
…So the treatments you're talking about is the amyloid antibodies, so licanumab and dinanumab.…
5 moments · sign in to read them all